Overview

Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection

Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of WPV01 in patients with mild/moderate COVID-19 infection
Phase:
Phase 2
Details
Lead Sponsor:
Westlake Pharmaceuticals (Hangzhou) Co., Ltd.